SLIDE 1 Wysocki J et al, Am J Physiol Renal Physiol May 3, 2017 (Epub ahead of print)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus Association of creatinine-adjusted urine concentration
- r activity of RAS pathway components with DKD in
people with type 1 diabetes
No DKD
Median (IQR)
DKD
Median (IQR)
OR (95%CI) p-value Angiotensinogen/Cr (µg/g) 15 (8, 24) 170 (18, 597) 2.2 (1.2, 3.3) 9.6 x 10-10 Cathepsin D/Cr (µg/g) 31 (22, 46) 147 (85, 219) 6.5 (3.5, 14.6) 2.3 x 10-14 ACE/Cr (µg/g) 0.8 (0.4, 1.4) 1.4 (0.9, 2.5) 2.2 (1.4, 3.9) 3.8 x 10-4 ACE activity/Cr (109 RFU/hr/g) 1.6 (1.0, 2.1) 1.0 (0.8, 1.2) 0.3 (0.1, 0.6) 4.6 x 10-4 ACE2/Cr (µg/g) 2.7 (1.7, 4.2) 4.1 (1.6, 5.7) 1.1 (0.8, 1.7) 0.54 ACE2 activity/Cr (106 RFU/hr/g) 0.3 (0.1, 0.9) 0.4 (0.2, 0.9) 1.2 (1.0, 1.4) 0.03 APA activity/Cr (106 RFU/hr/g) 22 (4, 89) 40 (11, 210) 1.2 (1.0, 1.3) 0.05
People with no DKD had eGFR >90 ml/min/1.73m2 and ACR <300 mg/g after >30 years of type 1 diabetes. Those with DKD had either an ACR >300 mg/g or both eGFR <60 ml/min/1.73m2 and ACR >30 mg/g.
SLIDE 2
Wysocki J et al, Am J Physiol Renal Physiol May 3, 2017 (Epub ahead of print)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus Association of urine concentration or activity of RAS pathway components with DKD in people with type 1 diabetes
OR (95%CI) p-value Age, years 0.9 (0.8, 1.0) 0.16 Non-white 1.8 (0.2, 14.8) 0.054 Female 0.5 (0.1, 2.6) 0.41 Diabetes duration, years 1.0 (0.9, 1.0) 0.31 Angiotensinogen/Cr (µg/g) 1.5 (0.9, 2.8) 0.11 Cathepsin D/Cr (µg/g) 6.5 (2.7, 22.4) 1.5 x 10-6 ACE activity/Cr (106 RFU/hr/g) 0.2 (0.1, 0.6) 0.003 ACE2 activity/Cr (103 RFU/hr/g) 1.0 (0.8, 1.4) 0.98 APA activity/Cr (106 RFU/hr/g) 0.9 (0.7, 1.2) 0.36
People with no DKD had eGFR >90 ml/min/1.73m2 and ACR <300 mg/g after >30 years of type 1 diabetes. Those with DKD had either an ACR >300 mg/g or both eGFR <60 ml/min/1.73m2 and ACR >30 mg/g.
SLIDE 3
Wysocki J et al, Am J Physiol Renal Physiol May 3, 2017 (Epub ahead of print)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus RAS pathway status in experimental DKD, based on urine concentration and enzymatic activity of RAS components
SLIDE 4
Wysocki J et al, Am J Physiol Renal Physiol May 3, 2017 (Epub ahead of print)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus RAS pathway status in human DKD, based on urine concentration and enzymatic activity of RAS components
